Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis
| Автори: | , , , , , , , , , , |
|---|---|
| Формат: | Conference item |
| Мова: | English |
| Опубліковано: |
Journal of Rheumatology
2022
|
| Резюме: |
|---|